Lung Cancer and \it{CYP1A1} or \it{GSTM1} Polymorphisms
10.1265/ehpm.7.230
- Author:
Tsunehiro OYAMA
;
Norio KAGAWA
;
Yong-Dae KIM
;
Akiko MATSUMOTO
;
Toyohi ISSE
;
Toshihiro KAWAMOTO
- Publication Type:Journal Article
- Keywords:
cytochrome p4501A1 gene (CYP1A1 ) polymorphism;
glutathione S-transferase μ gene (GSTM1) polymorphism;
p53 gene mutation;
non-small-cell lung cancer (NSCLC);
survival curve
- MeSH:
Malignant neoplasm of lung;
seconds;
CYP1A1 gene;
GST Gene;
Cytochrome P-450 CYP1A1
- From:Environmental Health and Preventive Medicine
2002;7(6):230-234
- CountryJapan
- Language:Japanese
-
Abstract:
Most chemical carcinogens are metabolized and activated in vivo by phase I enzymes including the microsomal cytochromes P450 and epoxide hydroxylases. The carcinogens and their metabolites are detoxified by phase II enzymes that include various transferases such as glutathion-S-transferases (GST). Increasing numbers of studies have demonstrated the association of the polymorphisms in GSTM1 (a member of GST) and CYP1A1 genes with the susceptibility to lung cancer. Subsequently, the polymorphisms appear to be important biomarkers that provide information for assessment of exposure and total burden of environmental carcinogens. Therefore, the investigation of the polymorphisms in these genes will provide information not only for the prediction of individual cancer risk but also for the prevention of cancer. In this review, we will summarize the polymorphisms in the GSTM1 and CYP1A1 genes and their relation to lung cancer susceptibility.
